Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.

<h4>Background</h4>The prevalence of thyroid nodules increases with age, average 4-7% for the U.S.A. adult population, but it is much higher (19-67%) when sub-clinical nodules are considered. About 90% of these lesions are benign and a reliable approach to their preoperative characteriza...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Armando Bartolazzi, Calogero D'Alessandria, Maria Gemma Parisella, Alberto Signore, Fabrizio Del Prete, Luca Lavra, Sten Braesch-Andersen, Roberto Massari, Carlo Trotta, Alessandro Soluri, Salvatore Sciacchitano, Francesco Scopinaro
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2008
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4829821531024d6984357829312b9852
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4829821531024d6984357829312b9852
record_format	dspace
spelling	oai:doaj.org-article:4829821531024d6984357829312b98522021-11-25T06:18:27ZThyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.1932-620310.1371/journal.pone.0003768https://doaj.org/article/4829821531024d6984357829312b98522008-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19020658/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The prevalence of thyroid nodules increases with age, average 4-7% for the U.S.A. adult population, but it is much higher (19-67%) when sub-clinical nodules are considered. About 90% of these lesions are benign and a reliable approach to their preoperative characterization is necessary. Unfortunately conventional thyroid scintigraphy does not allow the distinction among benign and malignant thyroid proliferations but it provides only functional information (cold or hot nodules). The expression of the anti-apoptotic molecule galectin-3 is restricted to cancer cells and this feature has potential diagnostic and therapeutic implications. We show here the possibility to obtain thyroid cancer imaging in vivo by targeting galectin-3.<h4>Methods</h4>The galectin-3 based thyroid immuno-scintigraphy uses as radiotracer a specific (99m)Tc-radiolabeled mAb. A position-sensitive high-resolution mini-gamma camera was used as imaging capture device. Human galectin-3 positive thyroid cancer xenografts (ARO) and galectin-3 knockout tumors were used as targets in different experiments in vivo. 38 mice with tumor mass of about 1 gm were injected in the tail vein with 100 microCi of (99m)Tc-labeled mAb to galectin-3 (30 microg protein/in 100 microl saline solution). Tumor images were acquired at 1 hr, 3 hrs, 6 hrs, 9 hrs and 24 hrs post injection by using the mini-gamma camera.<h4>Findings</h4>Results from different consecutive experiments show an optimal visualization of thyroid cancer xenografts between 6 and 9 hours from injection of the radiotracer. Galectin-3 negative tumors were not detected at all. At 6 hrs post-injection galectin-3 expressing tumors were correctly visualized, while the whole-body activity had essentially cleared.<h4>Conclusions</h4>These results demonstrate the possibility to distinguish preoperatively benign from malignant thyroid nodules by using a specific galectin-3 radio-immunotargeting. In vivo imaging of thyroid cancer may allow a better selection of patients referred to surgery. The possibility to apply this method for imaging and treatment of other galectin-3 expressing tumors is also discussed.Armando BartolazziCalogero D'AlessandriaMaria Gemma ParisellaAlberto SignoreFabrizio Del PreteLuca LavraSten Braesch-AndersenRoberto MassariCarlo TrottaAlessandro SoluriSalvatore SciacchitanoFrancesco ScopinaroPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 3, Iss 11, p e3768 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Armando Bartolazzi Calogero D'Alessandria Maria Gemma Parisella Alberto Signore Fabrizio Del Prete Luca Lavra Sten Braesch-Andersen Roberto Massari Carlo Trotta Alessandro Soluri Salvatore Sciacchitano Francesco Scopinaro Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
description	<h4>Background</h4>The prevalence of thyroid nodules increases with age, average 4-7% for the U.S.A. adult population, but it is much higher (19-67%) when sub-clinical nodules are considered. About 90% of these lesions are benign and a reliable approach to their preoperative characterization is necessary. Unfortunately conventional thyroid scintigraphy does not allow the distinction among benign and malignant thyroid proliferations but it provides only functional information (cold or hot nodules). The expression of the anti-apoptotic molecule galectin-3 is restricted to cancer cells and this feature has potential diagnostic and therapeutic implications. We show here the possibility to obtain thyroid cancer imaging in vivo by targeting galectin-3.<h4>Methods</h4>The galectin-3 based thyroid immuno-scintigraphy uses as radiotracer a specific (99m)Tc-radiolabeled mAb. A position-sensitive high-resolution mini-gamma camera was used as imaging capture device. Human galectin-3 positive thyroid cancer xenografts (ARO) and galectin-3 knockout tumors were used as targets in different experiments in vivo. 38 mice with tumor mass of about 1 gm were injected in the tail vein with 100 microCi of (99m)Tc-labeled mAb to galectin-3 (30 microg protein/in 100 microl saline solution). Tumor images were acquired at 1 hr, 3 hrs, 6 hrs, 9 hrs and 24 hrs post injection by using the mini-gamma camera.<h4>Findings</h4>Results from different consecutive experiments show an optimal visualization of thyroid cancer xenografts between 6 and 9 hours from injection of the radiotracer. Galectin-3 negative tumors were not detected at all. At 6 hrs post-injection galectin-3 expressing tumors were correctly visualized, while the whole-body activity had essentially cleared.<h4>Conclusions</h4>These results demonstrate the possibility to distinguish preoperatively benign from malignant thyroid nodules by using a specific galectin-3 radio-immunotargeting. In vivo imaging of thyroid cancer may allow a better selection of patients referred to surgery. The possibility to apply this method for imaging and treatment of other galectin-3 expressing tumors is also discussed.
format	article
author	Armando Bartolazzi Calogero D'Alessandria Maria Gemma Parisella Alberto Signore Fabrizio Del Prete Luca Lavra Sten Braesch-Andersen Roberto Massari Carlo Trotta Alessandro Soluri Salvatore Sciacchitano Francesco Scopinaro
author_facet	Armando Bartolazzi Calogero D'Alessandria Maria Gemma Parisella Alberto Signore Fabrizio Del Prete Luca Lavra Sten Braesch-Andersen Roberto Massari Carlo Trotta Alessandro Soluri Salvatore Sciacchitano Francesco Scopinaro
author_sort	Armando Bartolazzi
title	Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
title_short	Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
title_full	Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
title_fullStr	Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
title_full_unstemmed	Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
title_sort	thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
publisher	Public Library of Science (PLoS)
publishDate	2008
url	https://doaj.org/article/4829821531024d6984357829312b9852
work_keys_str_mv	AT armandobartolazzi thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT calogerodalessandria thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT mariagemmaparisella thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT albertosignore thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT fabriziodelprete thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT lucalavra thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT stenbraeschandersen thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT robertomassari thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT carlotrotta thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT alessandrosoluri thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT salvatoresciacchitano thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3 AT francescoscopinaro thyroidcancerimaginginvivobytargetingtheantiapoptoticmoleculegalectin3
_version_	1718413921953513472

Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.

Ejemplares similares